维格列汀

{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 470630169
| IUPAC_name = (S)-1-[N-(3-hydroxy-1-adamantyl)glycyl]pyrrolidine-2-carbonitrile
| image = Vildagliptin.svg
| alt = Skeletal formula
| image2 = Vildagliptin-3D-balls.png
| alt2 = Ball-and-stick model

| tradename = Galvus
| Drugs.com =
| licence_EU = Galvus
| pregnancy_category = Not recommended
| legal_UK = POM
| legal_status =
| routes_of_administration = 口服

| bioavailability = 85%
| protein_bound = 9.3%
| metabolism = 主要水解为非活性代谢物; CYP450没有明显参与
| elimination_half-life = 2-3小时
| excretion = 肾脏

| IUPHAR_ligand = 6310
| CAS_number_Ref =
| CAS_number = 274901-16-5
| ATC_prefix = A10
| ATC_suffix = BH02
| ATC_supplemental =
(with metformin)
| PubChem = 6918537
| DrugBank_Ref =
| DrugBank = DB04876
| ChemSpiderID_Ref =
| ChemSpiderID = 5293734
| UNII_Ref =
| UNII = I6B4B2U96P
| KEGG_Ref =
| KEGG = D07080
| ChEMBL_Ref =
| ChEMBL = 142703

| C=17 | H=25 | N=3 | O=2
| molecular_weight = 303.399 g/mol
| smiles = N#C[C@H]4N(C(=O)CNC13CC2CC(C1)CC(O)(C2)C3)CCC4
| InChI = 1/C17H25N3O2/c18-9-14-2-1-3-20(14)15(21)10-19-16-5-12-4-13(6-16)8-17(22,7-12)11-16/h12-14,19,22H,1-8,10-11H2/t12?,13?,14-,16?,17?/m0/s1
| InChIKey = SYOKIDBDQMKNDQ-XWTIBIIYBW
| StdInChI_Ref =
| StdInChI = 1S/C17H25N3O2/c18-9-14-2-1-3-20(14)15(21)10-19-16-5-12-4-13(6-16)8-17(22,7-12)11-16/h12-14,19,22H,1-8,10-11H2/t12?,13?,14-,16?,17?/m0/s1
| StdInChIKey_Ref =
| StdInChIKey = SYOKIDBDQMKNDQ-XWTIBIIYSA-N
| synonyms = (2S)-1-{2-[(3-hydroxy-1-adamantyl)amino]acetyl}pyrrolidine-2-carbonitrile
}}
維格列汀（），商品名為高糖優適，是一種二肽基肽酶-4抑制劑類口服抗糖尿病藥，用來治療第2型糖尿病。

维格列汀是唯一一种无论在高血糖或低血糖时都可以抑制胰高血糖素的物质。

引用